| Literature DB >> 30918282 |
Rui-Fang Xie1, Sheng Liu1, Ming Yang1, Jia-Qi Xu1, Zhi-Cheng Li2, Xin Zhou3.
Abstract
Ruyiping (RYP), a Chinese herbal formula, can remove toxin and clear nodular, showing ability of preventing postoperative recurrence of breast cancer. In this study, network was performed to predict possible targets, genes and pathways associated with RYP and breast cancer. Thin Layer Chromatography (TLC) and High Performance Liquid Chromatography (HPLC) were used to quantitatively study RYP formula and its single herbs. MTT methods, Luciferase reporter systems, zebrafish model and western blotting were respectively adopted to verify network prediction. Results showed that the quality of RYP could be controlled and icariin could be selected as mark ingredient; RYP expressed anti-breast tumor effects, which could be associated with inhibiting expression of Transforming Growth Factor β (TGFβ), promoting cells apoptosis and anti-angiogenesis. Parts of these results were consistent with network predictions in some degree, but not all. Network can help us narrow areas, focus on crucial factors, save money as well as time, but the results predicted by network should be confirmed by further experiments.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30918282 PMCID: PMC6437177 DOI: 10.1038/s41598-019-41243-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The flowchart of RYP application to breast cancer.
Results of target gene for breast cancer.
| Database | Gene/Locus name |
|---|---|
| OMIM | RAD54, S. cerevisiae, homolog-like |
| Prostate and breast cancer overexpressed 1 | |
| Estrogen receptor 1 | |
| Breast cancer metastasis suppressor 1 | |
| Breast cancer, type 3 | |
| Breast cancer antiestrogen resistance 1 | |
| Tumor protein p53 | |
| TTD | Receptor protein-tyrosine kinase erbB-4 |
| Transcription factor AP-1 | |
| RAC-alpha serine/threonine kinase; AkT | |
| Estrogen receptor alpha | |
| VEGF-2 receptor | |
| Erbb2 tyrosine kinase receptor | |
| Estradiol 17 beta dehydrogenase 1 | |
| Nuclear factor NF-kappa-B | |
| Estradiol 17 beta-dehydrogenase 1 | |
| Estrogen receptor | |
| Receptor protein-tyrosine kinase erbB-2 | |
| Estrogen receptor beta | |
| GeneCard | Tumor Protein P53 |
| Erb-B2 Receptor Tyrosine Kinase 2 | |
| Epidermal Growth Factor Receptor | |
| Estrogen Receptor 1 | |
| AKT Serine/Threonine Kinase 1 | |
| Epidermal Growth Factor | |
| BCL2 Associated X, Apoptosis Regulator | |
| Transforming Growth Factor Beta Receptor 2 | |
| Estrogen Receptor 2 | |
| Fibroblast Growth Factor Receptor 2 | |
| Fibroblast Growth Factor Receptor 1 | |
| Interleukin 6 | |
| SMAD Family Member 4 | |
| Vascular Endothelial Growth Factor A | |
| BCL2, Apoptosis Regulator | |
| Transforming Growth Factor Beta 1 | |
| Fibroblast Growth Factor Receptor 4 | |
| Signal Transducer And Activator Of Transcription 3 | |
| Mitogen-Activated Protein Kinase 1 | |
| Tumor Necrosis Factor | |
| Breast Cancer Anti-Estrogen Resistance 3 | |
| Vascular Endothelial Growth Factor C | |
| Fibroblast Growth Factor 2 | |
| BCL2 Like 1 | |
| Erb-B2 Receptor Tyrosine Kinase 3 | |
| Fibroblast Growth Factor Receptor 3 | |
| Transforming Growth Factor Alpha | |
| Tumor Necrosis Factor Superfamily Member 10 | |
| Interferon Gamma | |
| AKT Serine/Threonine Kinase 2 | |
| Transforming Growth Factor Beta Receptor 1 | |
| NFKB Inhibitor Alpha | |
| Interleukin 1 Beta | |
| SMAD Family Member 2 | |
| Erb-B2 Receptor Tyrosine Kinase 4 | |
| Signal Transducer And Activator Of Transcription 1 |
Results of chemical compounds in RYP.
| ChemName | ChemName | ||
|---|---|---|---|
| 1 | beta-elemene | 25 | Stigmasterol |
| 2 | Ginkgetin | 26 | luteolin |
| 3 | beta-sitosterol | 27 | apigenin |
| 4 | poriferast-5-en-3beta-ol | 28 | icariin |
| 5 | 13657-68-6 | 29 | beta-elemene |
| 6 | Besigomsin | 30 | Hemo-sol |
| 7 | bilobetin | 31 | quercetin |
| 8 | pulegone | 32 | hyperin/hyperoside |
| 9 | oleanolic acid | 33 | CAM |
| 10 | beta-sitosterol | 34 | Vetol |
| 11 | hydroxytyrosol | 35 | colchine |
| 12 | baohuoside i | 36 | icariin |
| 13 | isoliquiritigenin | 37 | DFV |
| 14 | salidroside | 38 | Robinetin |
| 15 | Hirsutrin | 39 | Isoginkgetin |
| 16 | 3,5,7-Trihydroxy-4′- methoxyl-8-prenylflavone -3-O-rhamnopyranoside | 40 | linolenic acid |
| 17 | tricin | 41 | NON |
| 18 | Germacron | 42 | Anhydroicaritin |
| 19 | emodin | 43 | lauric acid |
| 20 | oleanolic acid | 44 | TMH |
| 21 | Gastrodin | 45 | DOB |
| 22 | Terragon | 46 | Methyleugenol |
| 23 | Chryseriol | 47 | succinic acid |
| 24 | kaempferol |
Figure 2RYP’ Influence on enrichment of molecular functional (A), biological process (B), cellular components (C), KEGG signaling pathway (D), Reactome signaling pathway (E) and diseases (F).
Sources of Chinese herbal medicine.
| Herbs | Batch No. | Company | Origin |
|---|---|---|---|
| YYH | 2012122002 | Shanghai DeHua Pharmacutical Corporation | LiaoNing |
| 2012102901 | Shanghai DeHua Pharmacutical Corporation | LiaoNing | |
| 2012121401 | Shanghai HuaPu Pharmacutical Corporation | SiChuan | |
| 2013010906 | Shanghai HuaPu Pharmacutical Corporation | NeiMeng | |
| 2013012811 | Shanghai DeHua Pharmacutical Corporation | LiaoNing | |
| 2013012404 | Shanghai HuaPu Pharmacutical Corporation | SiChuan | |
| 2013082007 | Shanghai DeHua Pharmacutical Corporation | LiaoNing | |
| 2013100902 | Shanghai HuaPu Pharmacutical Corporation | LiaoNing | |
| 2013031903 | Shanghai HuaPu Pharmacutical Corporation | LiaoNing | |
| YT2013010901 | Shanghai YuTianCheng Pharmacutical Corporation | GanSu | |
| 130730-1 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | LiaoNing | |
| EZ | 131010-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | GuangXi |
| 130327 | Shanghai YangHeTang Pharmacutical Corporation | GuangXi | |
| 130604-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | GuangXi | |
| 130520-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | GuangXi | |
| 130625-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | SiChuan | |
| 121228 | Shanghai Kangqiao Pharmacutical Corporation | ZheJiang | |
| 130506-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | YunNan | |
| 130107 | Shanghai Kangqiao Pharmacutical Corporation | ZheJiang | |
| 130527-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | GuangXi | |
| 131025-2 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | SiChuan | |
| 130629 | Shanghai Kangqiao Pharmacutical Corporation | ZheJiang | |
| 130802-1 | Shanghai Wan Shi Cheng Reed Sinopharm Products Ltd | YunNan |
Figure 3Chromatographic fingerprints and synthetic scores for HHY (A,B), EZ (C,D) at 270 nm.
Figure 4Chromatograms for RYP decoction (A) and dry extract (B) at 270 nm.
Precision tests of HPLC.
| Peak NO. | Peak area | ||||||
|---|---|---|---|---|---|---|---|
| S1 | S2 | S3 | S4 | S5 | S6 | ||
| 1 | 1216.6 | 1224.4 | 1306.4 | 1307.9 | 1318.9 | 1228.7 | 3.82 |
| 2 | 990.2 | 994.6 | 979.1 | 982.8 | 985.4 | 987.3 | 0.55 |
| 3 | 589.2 | 593.8 | 572 | 578.3 | 564.9 | 576 | 1.86 |
| 4 | 3346.9 | 3345.6 | 3350.1 | 3359.7 | 3353.2 | 3348.1 | 0.15 |
| 5 | 335.1 | 335.6 | 330.5 | 362.7 | 357.4 | 335.8 | 3.96 |
| 6 | 1213.7 | 1217 | 1221.7 | 1227 | 1227.7 | 1215.4 | 0.49 |
| 7 | 120.4 | 120.7 | 114.8 | 121.9 | 116 | 120.3 | 2.42 |
Stability tests of HPLC.
| Peak NO. | Peak area | ||||||
|---|---|---|---|---|---|---|---|
| S1 | S2 | S3 | S4 | S5 | S6 | ||
| 1 | 693.1 | 696.1 | 695.6 | 704.8 | 700.5 | 698.5 | 0.59 |
| 2 | 852.2 | 854.4 | 861.6 | 864.2 | 857.6 | 855.8 | 0.53 |
| 3 | 585.9 | 581.9 | 597.4 | 598.8 | 600.6 | 586.9 | 1.34 |
| 4 | 3373.4 | 3381.4 | 3359.4 | 3391.2 | 3354.5 | 3362.3 | 0.42 |
| 5 | 303 | 304.3 | 264.6 | 303.7 | 288.2 | 306.5 | 5.53 |
| 6 | 833.4 | 846.7 | 823.9 | 838.2 | 828.8 | 840.4 | 0.99 |
| 7 | 115.5 | 112.8 | 113.9 | 116.4 | 116.8 | 114.5 | 1.33 |
The repeatability tests of HPLC.
| Peak NO. | Peak area | ||||||
|---|---|---|---|---|---|---|---|
| S1 | S2 | S3 | S4 | S5 | S6 | ||
| 1 | 652 | 726.2 | 675.8 | 598.9 | 701.5 | 633.9 | 6.96 |
| 2 | 806.4 | 891.2 | 830.9 | 795.2 | 794.7 | 793.1 | 4.68 |
| 3 | 553.3 | 620.5 | 580.2 | 534.3 | 534.8 | 535.4 | 6.20 |
| 4 | 3221.4 | 3486.4 | 3281 | 3281.2 | 3291.7 | 3233.6 | 2.91 |
| 5 | 387.2 | 316.4 | 336 | 329.4 | 329.2 | 356.1 | 7.45 |
| 6 | 798.6 | 859.5 | 809.6 | 868.5 | 877.3 | 888.5 | 4.38 |
| 7 | 110.5 | 121.3 | 114 | 117 | 119.1 | 111.3 | 3.75 |
Contents of icariin in decoction for HHY.
| Batch No. | Origin | Icariin (mg/g) |
|---|---|---|
| 2012122002 | LiaoNing | 1.0342 |
| 2012102901 | LiaoNing | 0.9247 |
| 2012121401 | SiChuan | 1.1752 |
| 2013010906 | NeiMeng | 0.8577 |
| 2013012811 | LiaoNing | 0.9096 |
| 2013012404 | SiChuan | 0.6924 |
| 2013082007 | LiaoNing | 0.5238 |
| 2013100902 | LiaoNing | 1.6818 |
| 2013031903 | LiaoNing | 0.9642 |
| YT2013010901 | GanSu | 1.7938 |
| 130730-1 | LiaoNing | 1.3638 |
| mean | 1.0837 | |
| RSD(%) | 36.20 |
Contents of icariin in dry extract and decoction of RYP.
| Batch No. | Sample | Content (mg/g) | RSD (%) |
|---|---|---|---|
| 20131209001 | Dry extract | 16.68 | |
| 20131209002 | Dry extract | 16.98 | 1.21 |
| 20131209003 | Dry extract | 17.08 | |
| 20131209004 | Decoction | 0.41 | |
| 20131209005 | Decoction | 0.41 | 0.60 |
| 20131209006 | Decoction | 0.41 |
Figure 5The effects of RYP decoction (A), RYP dry extract (B), YYH decoction (C) and icariin (D) combined with adriamycin on proliferation of MCF-7 cells (n = 3).
Figure 6The effects of RYP on ISVs of Tg(fli1:EGFP). Embryos were treated without (A) or with RYP decoction at 0.5 mg/ml (B), 1 mg/ml (C), 2 mg/ml (D), 4 mg/ml (E) from 24 hpf to 48 hpf. Each group had six to eight items of zebrafish. Each test was done in triple. The numbers of ISVs were recorded at 24 h (F).
Figure 7Effects of Herbs (A) and pure compounds (B) in RYP on growth of cell lines. The ratio of the average absorption value of drug group to blank group was calculated to evaluate toxicity of drugs on cell growth. Each data point was done in triplicate.
Luciferase assay.
| Cell Line | Signaling pathway | Agonist | Agonist con (ng/mL) | Agonist Incubate time(h) |
|---|---|---|---|---|
| 293 with AP-1 | TPA | 25 | 6 | |
| 293 with GAS | stat 1 | IFNγ | 12 | |
| 293 with ISRE | stat 1/2 | Interferon α(IFNα) | 6 | |
| 293 with NFκB | NFκB | TNFα | 25 | 6 |
| 293 with stat-3 | Stat 3 | Il-6 | 10 | 12 |
| 293 with TGFβ | Smad | TGFβ | 2.5 | 6 |
| 293 with Erα | Erα | 12 | ||
| 293 with Erβ | Erβ | 12 |
ISRE: Interferon-Sensitive Response Element.
STAT-3:Signal transducer and activator of transcription 3.
TPA:12-O-tetradecanoylphorbol-13-acetate.
TNFα: Tumor Necrosis Factor α.
Effects of pure compounds and herbs in RYP on luciferase activities.
| Cell lines | Stimulator | Icariin | Curcumol | Colchicine | Curcumin | BYZ | SCG | EZ | YYH | FF | RYP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 293 AP-1 | TPA | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) |
| 293 IRSE | IFNα | (−) | (−) | ↓ | ↓ | (−) | (−) | (−) | (−) | (−) | (−) |
| 293 NFκB | TNFα | (−) | (−) | (−) | ↓ | (−) | (−) | (−) | ↓ | (−) | (−) |
| 293 stat-3 | IL-6 | (−) | ↑ | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) |
| 293 TGFβ | TGFβ | (−) | (−) | (−) | ↓ | ↓ | (−) | (−) | ↓ | ↓ | ↓ |
| Erα | Erα | (−) | (−) | ↑ | (−) | ↓ | (−) | (−) | (−) | (−) | ↓ |
| Erβ | Erβ | (−) | (−) | (−) | ↓ | (−) | (−) | (−) | ↓ | ↓ | ↓ |
Figure 8Effects of RYP dry extract on protein expression. MCF-7 cell lines were incubated without or with RYP dry extract at 1 mg/ml, 3 mg/ml,10 mg/ml for 24 h. The proteins of cells were extracted and determined by western blotting. The pictures of BCl-2 (A), bax (A), parp (C) and p-Akt (D) were taken. Then protein pictures were analyzed with software. The BCl-2 (B), Bax (E), parp (G) and p-Akt (H) protein expressions were obtained and ratios of Bax to BCl-2 were calculated (F). Each experiment was done in triple.
Figure 9Effects of icariin on protein expression. MCF-7 cell lines were incubated without or with Icariin at 10 μM, 30 μM and 100 μM for 24 h. The proteins of cells were extracted and determined by western blotting. The pictures of BCl-2 (A), bax (A), parp (C) and p-Akt (D) were taken. Then protein pictures were analyzed with software. The Bax (B), p-Akt (D), BCl-2 (E), parp (F) and p-Akt (H) protein expressions were obtained and ratios of Bax to BCl-2 were calculated (F). Each experiment was done in triple. (The KDA of Parp is about 116 and the KDA of p-akt is about 60. After blocking, the membrane was cut on 70 kDa, actually these two proteins come from one gel, Therefore, the control in (C,D) was same.
Figure 10The workflow of network prediction.